Inhibition of Breast Cancer Regrowth and Pulmonary Metastasis in Nude Mice by Anti-gastric Ulcer Agent, Irsogladine
Springer Science and Business Media LLC - Tập 83 - Trang 195-199
Tóm tắt
Irsogladine is a commonly used anti-gastric ulcer agent in Japan, and recent in vivo studies have shown it to have anti-angiogenic properties. The exact role of irsogladine as an inhibitor of angiogenesis remains uncertain. In this study, we show that irsogladine inhibited breast cancer regrowth and pulmonary metastasis but had no anti-angiogenic function against HUVEC cells. Irsogladine failed to inhibit proliferation, tubular formation, and the uPA/MMP-1 mRNA expression of HUVEC cells. We also examined the effect of irsogladine in an orthotopic transplant model of human breast cancer metastasis in athymic mice. Human MDA-MB-435 cells were injected into the mammary fat pads. After 9 weeks, the tumors were resected under general anesthesia. Irsogladine or vehicle was given p.o. daily thereafter. Daily administration of irsogladine at 120 mg/kg per day over a 5-week period had no effect on the body weight of the mice. Tumor regrowth, average volume of pulmonary metastases, and the number of metastases were inhibited by 40, 48 and 64%, respectively. These results suggest that irsogladine may be useful in the breast cancer adjuvant setting.
Tài liệu tham khảo
Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 324: 1–8, 1991
Fidler LJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 85–88, 1994
Barinaga M: Designing therapies that target tumor blood vessels. Science 275: 482–484, 1997
Twardowski P, Gradishar WJ: Clinical trial of antiangiogenic agents. Curr Opin Oncol 9: 584–589, 1997
Tsuruoka N, Sugiyama M, Tawaragi Y, Tsujimoto M, Nishihara T, Goto T, Sato N: Inhibition of in vitro angiogenesis by lymphotaxin and interferon-gamma. Biochem Biophys Res Commun 155: 429–435, 1988
Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline. Cancer Res 51: 672–675, 1991
Gagliardi A, Collins DC: Inhibition of angiogenesis by antiestrogens. Cancer Res 53: 533–535, 1993
D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085, 1994
Ueda F, Kyoi T, Mimura K, Kimura K, Yamamoto M: Intercellular communication in cultured rabbit gastric epithelial cells. Jpn J Pharmacol 57: 321–328, 1991
Sato Y, Morimoto A, Kiue A, Okamura K, Hamanaka R, Kohno K, Kuwano M, Sakata, T: Irsogladine is a potent inhibitor of angiogenesis. FEBS Lett 322: 155–158, 1993
Ono M, Kawahara N, Goto D, Wakabayashi Y, Ushiro S, Yoshida S, Izumi H, Kuwano M, Sato Y: Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine. Cancer Res 56: 1512–1516, 1996
Sledge Jr GW, Qulali M, Goulet R, Bone EA, Fife R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546–1550, 1995
Nozaki S, Sledge Jr GW, Nakshatri H: Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem Biophys Res Commun 275: 60–62, 2000
Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet Jr RJ, Sledge Jr GW, Nakshatri H: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19: 4159–4169, 2000
Hosokawa T, Otani Y, Ogawa K, Kajiwara T: Complete disappearance of metastatic abdominal tumors from gastric cancer after treatment with irsogladine maleate. J Cancer Res Clin Oncol 118: 565–566, 1992
Hosokawa T, Ogawa K, Otani Y, Kajiwara T: Two cases of gastric cancer remarkably reduced with a combined dosage of irsogladine maleate preparation and UFT. Oncol Rep 1: 93–95, 1994
Sugie S, Okamoto K, Ueda F, Watanabe T, Tanaka T, Mori H: Suppressive effect of irsogladine maleate on diethylnitrosamine-initiated and phenobarbital-prompted hepatocarcinogenesis in male F344 rats. Jpn J Cancer Res 89: 371–376, 1998
Hirose Y, Tanaka T, Makita H, Yang M, Satoh K, Hara A, Maeda M, Toriyama HB, Mori H, Tsuda H: Suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compounds on azoxymethane-induced aberrant crypt foci in rat colon. Jpn J Cancer Res 87: 549–554, 1996
Janicke F, Schmitt M, Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemostas 17: 303–312, 1991